Nanotechnology-mediated targeting of tumor angiogenesis
2011

Nanotechnology in Targeting Tumor Angiogenesis

publication Evidence: moderate

Author Information

Author(s): Deboshri Banerjee, Rania Harfouche, Shiladitya Sengupta

Primary Institution: Brigham and Women's Hospital, Harvard Medical School

Hypothesis

Can nanotechnology improve the targeting of tumor-associated angiogenesis for cancer therapy?

Conclusion

Nanotechnology offers significant advantages in targeting tumor angiogenesis, potentially improving the efficacy and safety of cancer therapies.

Supporting Evidence

  • Nanoparticles can carry high payloads of therapeutic agents and improve drug half-life.
  • Targeting tumor vasculature can reduce systemic toxicity compared to conventional chemotherapy.
  • Nanotechnology allows for non-invasive imaging of tumor angiogenesis.

Takeaway

Scientists are using tiny particles to help deliver medicine directly to tumors, making treatments work better and cause fewer side effects.

Methodology

The review discusses various types of nanoparticles and their applications in targeting tumor angiogenesis, including passive and active targeting mechanisms.

Limitations

Many anti-angiogenic therapies still struggle with poor biodistribution and low efficacy due to systemic administration.

Digital Object Identifier (DOI)

10.1186/2045-824X-3-3

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication